Ovarian
ablation after chemotherapy in patients who continue to menstruate
Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 3 2000
Play
Audio Below:
I
think it’s a really exciting strategy. I do have some reservations
about whether or not we’d be able to do it, but there is talk
within the Intergroup structure of trying to mount a trial. It would
really be kind of a niche trial because you’d have to have
what you said. You’d have to have a woman, who takes chemotherapy,
who still has evidence of menstrual function at the end of that,
and so you’re going to have to have a pretty big funnel to
come down to those folks, I think. And then you’d have to have
a randomization to an ovarian ablation strategy versus not. And
I think most people would kind of automatically put those women
on tamoxifen, so that’s also going to muddy the waters a little
bit, it seems to me. But I know that several U.S. investigators,
especially the folks in the north central group, they’re actually
talking about joining an international breast cancer study group
trial that wants to look at this question. So it may come, maybe
through an international collaboration.
Combined
endocrine therapy for breast cancer - New life for an old idea? Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins
Oncol Ctr 1650 Orleans St,Rm 409 Baltimore, MD 21231 USA). Journal
of the National Cancer Institute 92(11):859-860, 2000 Jun 7. No
abstract
